ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES
Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease characterized by chronic inflammation of the synovial membrane of joints and by a wide spectrum of extra-articular (systemic) manifestations, with the pathological T cell activation that plays a key role in the pathogenesis of this...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2130 |
| Summary: | Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease characterized by chronic inflammation of the synovial membrane of joints and by a wide spectrum of extra-articular (systemic) manifestations, with the pathological T cell activation that plays a key role in the pathogenesis of this disease. Therefore, the design of abatacept (ABC) that selectively inhibits T cell costimulation occupies a special place among various approaches to the pathogenetic therapy of RA. The review gives novel evidence for the efficacy and safety of its subcutaneous formulation and discusses its mechanism of action in suppressing the synthesis of autoantibodies and in restoring normal regulatory T cell function,etc. Mechanisms for the synergic action of ABC and methotrexate for RA and prospects for personified medicine in rheumatology are specially considered using the drug as an example. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |